Regenxbio (RGNX) Accounts Payables (2014 - 2025)

Regenxbio's Accounts Payables history runs 12 years deep, the most recent figure standing at $21.4 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 6.32% year-over-year to $21.4 million; the TTM figure through Dec 2025 stood at $21.4 million (down 6.32% YoY), while the FY2025 annual figure was $21.4 million, down 6.32% from the prior year.
• Accounts Payables was $21.4 million for Q4 2025 at Regenxbio, down from $22.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $31.4 million in Q1 2024 to a low of $9.4 million in Q2 2021.
• Historically, Accounts Payables has averaged $20.0 million across 5 years, with a median of $21.5 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 138.98% in 2022, then slumped 39.27% in 2025.
• A 5-year view of Accounts Payables shows it stood at $11.4 million in 2021, then jumped by 138.98% to $27.2 million in 2022, then slipped by 16.27% to $22.8 million in 2023, then rose by 0.05% to $22.8 million in 2024, then declined by 6.32% to $21.4 million in 2025.
• The last three Accounts Payables figures came in at $21.4 million (Q4 2025), $22.3 million (Q3 2025), and $21.7 million (Q2 2025), per Business Quant data.